The literature indicates the recent development of numerous selective P2X3 antagonists (such as Gefapixant); however, further investigations into the underlying pathological pathways are crucial to harness their potential in the conservative management of hydronephrosis [13,37,38,39]. The gene discussed is P2RX3; the disease is hydronephrosis.